3-Tert-butyl-4-ethyl-1,2-oxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-Tert-butyl-4-ethyl-1,2-oxazole
• 英文别名: 3-tert-butyl-4-ethyl-1,2-oxazole
• 化学式: C₉H₁₅NO
• 分子量: 153.22
• InChiKey: MHEROGOVVTWGEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• N-LINKED HETEROCYCLIC ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
  申请人：Qiao Jennifer

  公开号：US20100197716A1

  公开（公告）日：2010-08-05

  The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y 1 receptor which can be used as medicaments.

  本发明提供了一种新型尿素，包含式（I）中的N-芳基或N-杂环芳基取代的杂环，或其立体异构体、互变异构体、药学上可接受的盐或溶剂形式，其中变量A、B、D和W如本文所定义。这些化合物是人类P2Y1受体的选择性抑制剂，可用作药物。
• RIP1 inhibitory compounds and methods for making and using the same
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US11370765B2

  公开（公告）日：2022-06-28

  Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.

  本文公开了激酶抑制化合物，如受体相互作用蛋白-1（RIP1）激酶抑制剂化合物，以及包含此类抑制化合物的药物组合物和组合物。所公开的化合物、药物组合物和/或组合物可用于治疗或预防激酶相关疾病或病症，尤其是 RIP1 相关疾病或病症。
• RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20210002237A1

  公开（公告）日：2021-01-07

  Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
• US7550499B2
  申请人：——

  公开号：US7550499B2

  公开（公告）日：2009-06-23
• US7700620B2
  申请人：——

  公开号：US7700620B2

  公开（公告）日：2010-04-20